{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "binds",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P01133",
      "entity_text" : "epidermal growth factor",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ01498",
      "entity_text" : "emicizumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "binding_site" : [ "(EGF)-like domains" ],
    "context" : {
      "TissueType" : [ "tissuelist:TS-0800" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "We anticipated that emicizumab would be unlikely to interfere with the actions of AT or TFPI, because emicizumab binds the epidermal growth factor (EGF)-like domains of FIXa and FXa, while AT and TFPI bind the protease domains, and because its binding affinities are on the order of 1 micromolar.",
  "reading_complete" : "2020-08-02T11:54:10Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T11:52:35Z",
  "trigger" : "binds",
  "evidence" : [ "emicizumab binds the epidermal growth factor (EGF)-like domains" ],
  "pmc_id" : "6524866",
  "score" : 0
}